Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Status: | Completed |
---|---|
Conditions: | Liver Cancer, Liver Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 6/9/2017 |
Start Date: | June 6, 2016 |
End Date: | April 6, 2017 |
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
The primary objective of this study is to estimate the frequency of FGFR2 fusions in
archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma
(HCC-CCA) tumor samples
archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma
(HCC-CCA) tumor samples
This is a non-interventional, observational study of archived human tissue samples; no
surgical procedures will be required and no treatment will be provided as part of this
study. Approximately 150 archived tissue samples obtained from patients with iCCA or mixed
HCC-CCA will be analyzed for somatic alteration status and will include
cholangiocarcinoma-specific FGFR2 fusion isoforms.
surgical procedures will be required and no treatment will be provided as part of this
study. Approximately 150 archived tissue samples obtained from patients with iCCA or mixed
HCC-CCA will be analyzed for somatic alteration status and will include
cholangiocarcinoma-specific FGFR2 fusion isoforms.
Inclusion Criteria:
- If required by law or local regulations (i.e., the sample is from an identifiable
subject), signed written informed consent should be granted prior to use of the
sample in the study
- ≥ 18 years of age
- Histologically or cytologically confirmed iCCA or mixed HCC-CCA, who are/were
eligible for systemic therapy (samples collected prior to initiation of the systemic
therapy may be submitted for testing)
- Have one or more formalin fixed and paraffin embedded blocks available. If blocks are
not evaluable, 7-10 unstained, non-baked slides with 5-micron thick sections with at
least 20% tumor tissue should be available. (Potential participants who are scheduled
to undergo surgical treatment may agree to provide surplus of tissues not required
for diagnosis and have to provide informed consent prior to the surgery.)
Exclusion Criteria:
- Not applicable: Patients must meet all of the inclusion criteria.
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials